Health and Healthcare
Cramer Speculates on Dialysis Drug (AMAG, XCR)
Published:
Last Updated:
On tonight’s MAD MONEY on CNBC, Jim Cramer said he had a speculative biotech stock. His pick in the sector is AMAG Pharmaceuticals, Inc. (AMAG) because of its soon to be approved ferumoxytol, a newer and better intravenous iron treatment for kidney disease patients on dialysis. Cramer thinks there are many reasons to like this one:
We recently covered a speculative portable dialysis device maker (in prototype and development stage) on our "10 Stocks Under $10" called Xcorporeal, Inc. (AMEX: XCR) which has risen in the last two weeks since being included. We have also reviewed some of the lower-tier dialysis names for this as well.
We would note that this AMAG traded at $56.00 after an upgrade just in early February and shares closed under $40.00 Friday.
Jon C. Ogg
March 28, 2008
Jon Ogg produces the Special Situation Investing Newsletter and he can be reached at [email protected]; he does not own securities in the companies he covers.
Credit card companies are at war, handing out free rewards and benefits to win the best customers. A good cash back card can be worth thousands of dollars a year in free money, not to mention other perks like travel, insurance, and access to fancy lounges. See our top picks for the best credit cards today. You won’t want to miss some of these offers.
Flywheel Publishing has partnered with CardRatings for our coverage of credit card products. Flywheel Publishing and CardRatings may receive a commission from card issuers.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.